Dabrafenib and Trametinib for Melanoma and Other Cancers
Dabrafenib and/or Trametinib Rollover Study
Recruiting
Phase 4
Interventional Study
Melanoma
Non Small Cell Lung Cancer
Solid Tumor
Rare Cancers
High Grade Glioma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 100
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
Who this trial is looking for
This trial is looking for patients currently treated with dabrafenib or trametinib who can continue their treatment. If the doctor thinks you are benefiting from your current treatment, you may be eligible to enroll.
Are You a Good Fit for This Trial?
You may be able to join if
- I am currently receiving treatment with dabrafenib or trametinib.
- I am in a Novartis or former GSK sponsored study.
- I have fulfilled the requirements for the primary objective.
- My doctor thinks I would benefit from continued treatment.
You may not be able to join if
- I have been permanently discontinued from study treatment in the parent protocol.
- My treatment is already available and reimbursed in my country.
- I currently have unresolved side effects that caused an interruption in my treatment.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
* In the opinion of the Investigator would benefit from continued trea…
Contacts